Impact of Weight on Clinical Outcomes of Edoxaban Therapy in Atrial Fibrillation Patients Included in the ETNA-AF-Europe Registry.

ABSTRACT:

Background

Extremes of body weight may alter exposure to non-vitamin K antagonist oral anticoagulants and thereby impact clinical outcomes. This ETNA-AF-Europe sub-analysis assessed 1-year outcomes in routine care patients with atrial fibrillation across a range of body weight groups treated with edoxaban.

Methods

ETNA-AF-Europe is a multinational, multicentre, observational study conducted in 825 sites in 10 European countries. Overall, 1310, 5565, 4346 and 1446 enrolled patients were categorised into ≤60 kg, >60-≤80 kg (reference weight group), >80-≤100 kg and >100 kg groups.

Results

Patients weighing ≤60 kg were older, more frail and had a higher CHA₂DS₂-VASc score vs. the other weight groups. The rates of stroke/systemic embolism, major bleed

SUBMITTER: Boriani G 

PROVIDER: S-EPMC8269173 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature